tadalafil PAH
Selected indexed studies
- Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. (JAMA, 2022) [PMID:35412560]
- Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. (J Am Coll Cardiol, 2024) [PMID:38267108]
- Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities. (Eur J Heart Fail, 2024) [PMID:38966990]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. (2022) pubmed
- Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. (2024) pubmed
- Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities. (2024) pubmed
- Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis. (2024) pubmed
- New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review. (2024) pubmed
- Tadalafil. (2026) pubmed
- Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. (2019) pubmed
- PMID:37797132 (2022) pubmed
- Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. (2021) pubmed
- Tadalafil Use in Cardiovascular Disease. (2025) pubmed